Previous 10 |
home / stock / casbf / casbf news
LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...
Without naming China, Singapore researchers ( Le Bert et al. 2020 ) suggest that T cell cross-reactivity to COVID-19 viral epitopes found in all 23 persons tested 17 years after recovering from the 2003 SARS may "explain some of the differences in infection rates or pathology observed duri...
Deals and Financings Shanghai Hansoh Pharma (HK: 3692) obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment plus milestones of up to $68 million. It will also pay royalties on sales. TRN-000632 is an investigatio...